Mayo Clinic Laboratories’ IBDP2 serology panel detects for the presence of antibodies against Saccharomyces cerevisiae IgA and IgG, and anti-neutrophil cytoplasmic antibodies (pANCA) to confirm disease presence in patients for whom diagnosis is unclear. In this test specific episode of the  "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.

“Ulcerative colitis and Crohn's disease are really clinical diagnoses where the physician takes into account the clinical picture, some imaging studies, and maybe pathology to make a diagnosis,” Dr. Snyder says. “And for most patients, this is enough. Inflammatory bowel disease serology testing can be useful in a small subset of patients to help when it's difficult to differentiate between ulcerative colitis and Crohn's disease.”

Inflammatory bowel disease serology testing at Mayo Clinic Laboratories incorporates measures that improve testing quality and ensure accuracy of test results, Dr. Snyder adds. “We want to make sure that when we provide a result to a patient, the patient can rely on that result, the physician can rely on that result.”

Listen to learn more about how IBDP2 can help distinguish between ulcerative colitis and Crohn’s disease for some patients with IBD.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

IBDP2  | Inflammatory Bowel Disease Serology Panel, Serum

Useful information

• Distinguishing between ulcerative colitis and Crohn disease in patients for whom the specific diagnosis is unclear based on endoscopic, pathologic, and imaging evaluations.
• This test is not useful for determining the extent of disease in patients with inflammatory bowel disease or determining the response to disease-specific therapy including surgical resection of diseased intestine.

Specimen requirements

Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 1 mL

Performance information

• Analytic time: Same day/1 day
• Day(s) and time(s) performed: TBD

The latest

New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D.

May 14, 2024

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jacob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

View MoreView Less